Xinxiang Ruicheng Technology Co., Ltd. (hereinafter referred to as "Ruicheng Technology"), established in 2000 and headquartered in the eastern section of Qinglong Road, Xinxiang Economic Development Zone, is a high-tech enterprise integrating R&D, production, and sales. The company focuses on the development and industrialization of nucleoside and antiviral APIs and vitamin intermediates. Its core products include nucleoside pharmaceutical intermediates such as adenine, cytosine, tetraacetylribose, and hypoxanthine, which are widely used in the production of antiviral APIs.

The company possesses provincial-level R&D center qualifications and has established joint laboratories with universities such as Huazhong University of Science and Technology and Tianjin University of Science and Technology. Its R&D investment has maintained a leading position in the industry for many consecutive years. The company has passed ISO triple management system certification (quality, environment, and occupational health) and obtained Indonesian HALAL and Kosher certifications, ensuring its products meet international mainstream market access standards.